TRUDHESA Drug Patent Profile
✉ Email this page to a colleague
When do Trudhesa patents expire, and what generic alternatives are available?
Trudhesa is a drug marketed by Jn Bidco and is included in one NDA. There are six patents protecting this drug.
This drug has sixty-four patent family members in sixteen countries.
The generic ingredient in TRUDHESA is dihydroergotamine mesylate. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trudhesa
A generic version of TRUDHESA was approved as dihydroergotamine mesylate by PADAGIS US on April 28th, 2003.
Summary for TRUDHESA
| International Patents: | 64 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 49 |
| Patent Applications: | 1,250 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TRUDHESA |
| What excipients (inactive ingredients) are in TRUDHESA? | TRUDHESA excipients list |
| DailyMed Link: | TRUDHESA at DailyMed |
Pharmacology for TRUDHESA
| Drug Class | Ergotamine Derivative |
Anatomical Therapeutic Chemical (ATC) Classes for TRUDHESA
US Patents and Regulatory Information for TRUDHESA
TRUDHESA is protected by six US patents and one FDA Regulatory Exclusivity.
Patents protecting TRUDHESA
Nasal drug delivery device
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Nozzles for nasal drug delivery
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Intranasal delivery of dihydroergotamine by precision olfactory device
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
In-line nasal delivery device
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Nasal drug delivery device
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Nozzles for nasal drug delivery
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
FDA Regulatory Exclusivity protecting TRUDHESA
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jn Bidco | TRUDHESA | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 213436-001 | Sep 2, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Jn Bidco | TRUDHESA | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 213436-001 | Sep 2, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Jn Bidco | TRUDHESA | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 213436-001 | Sep 2, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TRUDHESA
See the table below for patents covering TRUDHESA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 107376071 | 用于将化合物递送到使用者的上部嗅觉区的喷嘴 (Nozzle for use in delivering a mixture of aerosol propellant and drug formulation) | ⤷ Try a Trial |
| European Patent Office | 3679971 | DISPOSITIF D'ADMINISTRATION DE MÉDICAMENT PAR VOIE NASALE (NASAL DRUG DELIVERY DEVICE) | ⤷ Try a Trial |
| Israel | 257845 | התקן קווי למתן דרך האף (In-line nasal delivery device) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
